Characteristic | Value |
---|---|
Age (median, range) | 54.1 (34.5–77.4) |
Tumor subtype | |
Hormone-positive | 16 (64%) |
TNBC | 9 (36%) |
Histology | |
Ductal | 18 (72%) |
Lobular | 4 (16%) |
Other | 3 (12%) |
Time (months) from diagnosis of metastatic disease (median, range) | 18.1 (2–116) |
Time (months) receiving bevacizumab before registration (median, range) | 8.4 (1.6–24.7) |
Number of previous treatment lines for metastatic disease | |
1 | 3 (12%) |
2 | 9 (36%) |
3 | 3 (12%) |
4 | 7 (28%) |
5 | 2 (8%) |
7 | 1 (4%) |
Companion drug in the pre-trial regimen: | |
Capecitabine | 13 (52%) |
Paclitaxel | 10 (40%) |
Docetaxel | 1 (4%) |
Cisplatin | 1 (4%) |
ECOG 0 | 15 (60% |
ECOG 1 | 10 (40%) |
PD-L1 expression: | |
Positive (> 1%) | 4 (16%) |
Negative (0%) | 16 (64%) |
Unknown | 5 (20%) |